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Development of a framework to improve
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framework
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Abstract
Background: Research has shown that recruitment to trials is a process that stretches from identifying potentially
eligible patients, through eligibility assessment, to obtaining informed consent. The length and complexity of this
pathway means that many patients do not have the opportunity to consider participation. This article presents the
development of a simple framework to document, understand and improve the process of trial recruitment.
Methods: Eight RCTs integrated a QuinteT Recruitment Intervention (QRI) into the main trial, feasibility or pilot
study. Part of the QRI required mapping the patient recruitment pathway using trial-specific screening and
recruitment logs. A content analysis compared the logs to identify aspects of the recruitment pathway and
process that were useful in monitoring and improving recruitment. Findings were synthesised to develop an
optimised simple framework that can be used in a wide range of RCTs.
Results: The eight trials recorded basic information about patients screened for trial participation and randomisation
outcome. Three trials systematically recorded reasons why an individual was not enrolled in the trial, and further details
why they were not eligible or approached, or declined randomisation. A framework to facilitate clearer recording of the
recruitment process and reasons for non-participation was developed: SEAR – Screening, to identify potentially eligible
trial participants; Eligibility, assessed against the trial protocol inclusion/exclusion criteria; Approach, the provision of oral
and written information and invitation to participate in the trial, and Randomised or not, with the outcome
of randomisation or treatment received.
Conclusions: The SEAR framework encourages the collection of information to identify recruitment obstacles
and facilitate improvements to the recruitment process. SEAR can be adapted to monitor recruitment to most
RCTs, but is likely to add most value in trials where recruitment problems are anticipated or evident. Further
work to test it more widely is recommended.
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Background
Randomised controlled trials (RCTs) are regarded as the
most reliable and effective method to evaluate healthcare
interventions. However, many RCTs struggle to recruit
to target and to time, leading to underpowered studies,
costly extensions or the early closure of studies [1–3].
Qualitative research has shown that the process of re-
cruitment can be complex, protracted and fragile [4, 5].
The Qualitative research Integrated within Trials (Quin-
teT) Recruitment Intervention (QRI) uses standard and
innovative qualitative research methods and simple
quantification techniques to understand the recruitment
process, and identify and address challenges as they
emerge [6]. An integral part of the QRI involves map-
ping the pathway to recruitment for potential partici-
pants, to better understand barriers to recruitment
across the trial and between clinical centres in multicen-
tre trials.
Maintaining an accurate record of patients considered
for RCT participation is a recommendation in Consoli-
dated Standards of Reporting Trials (CONSORT) report-
ing guidelines. Trials should present the numbers
assessed for eligibility, and excluded because they did
not meet the inclusion criteria, they declined to take
part, or ‘other reason’. [7]. The CONSORT flowchart
does not however, explicitly represent all the steps in the
pathway that potential RCT participants can follow. Fur-
thermore, reviews of published RCT results have shown
that trials consistently fail to record participant flow
accurately, particularly before informed consent and ran-
domisation [3, 8].
The collection of screening data is also a consideration
under Good Clinical Practice (GCP), in particular to
monitor compliance with the trial protocol inclusion
and exclusion criteria [9]. However, the literature on
screening logs is sparse and there is little consensus
about what to collect or how to collect it efficiently. As
the QRI includes analysis of data collected during
screening and eligibility assessment, we investigated the
range of data collected in eight RCTs with the aim of
developing a simple framework that could be applied to
most trials, to provide basic information useful to under-
stand recruitment challenges and improve the recruit-
ment process.
Methods
All trials which had worked with the QuinteT researchers
to optimise recruitment and informed consent were
considered for inclusion (n = 14). Six trials considered in
previous development work to map the recruitment path-
way were excluded [4, 5, 10]. Eight trials anticipating or
experiencing recruitment difficulties were included using
a convenience sampling approach. The eight RCTs were
managed by seven different clinical trials units (CTUs);
three were feasibility studies, two pilot studies and three
main trials. Ethical approval for the QRI research, includ-
ing the use of screening log data, was obtained within the
governance arrangement for each RCT.
We use the term ‘screening’ or ‘recruitment’ log to
refer to an “essential document that records all individ-
uals who entered pre-screening or screening, and details
the reasons why an individual is not enrolled ” [11]. Fol-
lowing this definition, we focused on two functions of a
screening log:
1. to record key characteristics of all individuals
considered for trial participation
2. to capture the reasons why an individual was not
enrolled in a trial
We conducted a directed content analysis [12] of the
screening logs used in the eight trials, to identify which
aspects of the recruitment pathway and process were
assessed and which were useful to monitor recruitment.
We reviewed all trial documentation [protocol, manual,
case report forms (CRFs), screening logs] and extracted
all references to recruitment, screening, screening log,
eligibility checks, information provision, and randomisa-
tion. Data were analysed thematically and synthesised
using the constant comparative method, adapted from
grounded theory [13, 14].
As part of the thematic analysis, codes were developed
to summarise the information included in each screen-
ing log. The codes were used to identify the recruitment
stages. The thematic analysis was conducted independ-
ently by the first author (CW) and the trial-specific
QuinteT researcher (DE, MJ, SP, LR, and SS). The codes
were presented to the wider group (DE, MJ, SP, LR, SS,
CW, and JD) to develop a consensus about the key
stages in the recruitment process that could be captured
by a log. The stages (screening, eligibility assessment,
approaching, and recruited/randomised) were then used
to conduct a directed content analysis to identify how
each trial recorded this information. The findings from
the content analysis were further synthesised by CW to
produce the SEAR framework. The recommendations
presented in the article were developed by CW and JD,
and are a synthesis of the findings from this study, com-
bined with experience from other QRIs in RCTs address-
ing recruitment problems.
Results
Characteristics of RCTs and recruitment pathway
The eight RCTs were funded by major UK public fund-
ing bodies. Recruitment to all RCTs was NHS hospital-
based and compared treatments for cancer (five trials)
and other chronic health conditions (three trials). Six
out of the eight trials included at least one surgical arm
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and four RCTs had a ‘no’ or ‘less’ treatment arm
(Table 1). Recruitment to all trials was doctor-led with
support from research nurses and other clinical staff.
The recruitment target for the majority of trials was less
than 350, with the exception of T5 and T6.
In all trials, the recruitment process was protracted due
to tests to determine eligibility (all RCTs), the necessity of
pre-trial treatment (T1, T3, T4), collaboration across med-
ical specialisms (T1, T3, T5, T7), and/or new care pathways
to recruit and treat RCT participants (T1, T5, T7). As part
of the QuinteT Recruitment Intervention (QRI), all RCTs
were encouraged to create and maintain comprehensive re-
cords of all individuals screened for trial participation to
generate basic data about levels of eligibility and recruit-
ment, and identify points at which potential participants
opted in or out of the RCT, or were lost from the process.
All screening logs were designed by the RCT CTU, or
trial manager (TM) and clinical lead (T4, T7 only). In gen-
eral, the chief investigators (CI), trial managers and CTUs
were committed to keeping screening records up to date,
despite the time and effort required to do so. Research
nurses in several trials reported informally that maintain-
ing screening records was a low priority compared to
other trial tasks. Trials with a particularly long or complex
recruitment pathway, trials for rare conditions, pilot and
feasibility studies showed greater commitment to keep
screening records up to date, even though similar instruc-
tions were included in all trial protocols.
Screening logs to map the recruitment pathway
All trial protocols included instructions to keep a record
of all participants screened for trial participation.
Screening records were mentioned as part of the QRI
section of the protocol (T2, T5, T8) or in the main
protocol or trial manual (T1, T3, T4, T6, T7). The most
comprehensive description included a section on recruit-
ment which outlined how patients should be identified
and logged, and an explanation of the purpose of keep-
ing up-to-date screening logs: to monitor and improve
recruitment, assess compliance with the trial protocol,
identify variations in recruitment between centres,
and identify points where patients were ‘lost’ from the
RCT (T1).
The majority of trials (except T6 and T7) requested in-
formation about potential trial participants on a ‘centre’
log – a landscape document, using one row to record
between 10 and 15 pieces of information per screened
participant, usually returned to the CTU every month,
excluding any patient identifiable data (e.g. initials or
hospital number), in accordance with GCP guidelines.
Three trials (T4, T6, T7) used an ‘individual’ screening
log to map the patient pathway, similar in style to a case
report form (CRF). Anonymised data (excluding any pa-
tient identifiers) were input from the CRF form into a
database to share information with the CTU. Individual
screening logs recorded more information, between 22
and 68 pieces of data, per screened participant. An
Table 1 RCT characteristics
Clinical
context
RCT type Clinical
centres
(n)
Target
recruitment
figure (n)
Specialties
involved
Intervention arms Trial-specific recruitment pathway challenge
T1 Cancer
treatment
Main 71 345 Surgery,
oncology
Chemotherapy;
surveillance (2)
Pre-trial treatment. Recruitment across surgery/
oncology. Alternative care pathway for trial.
Multiple tests/ delays determining eligibility.
T2 Orthopaedics Main 14 300 Surgery Surgery; placebo
surgery; active
monitoring (3)
Patients referred from GPs for treatment X.
T3 Cancer Feasibility 35 313 Surgery,
oncology
Chemotherapy; test-
directed chemotherapy (2)
Pre-trial treatment. Recruitment across surgery/
oncology.
T4 Cancer Pilot 2 36 Surgery Open surgery; minimally
invasive surgery (2)
Pre-trial treatment. Recruitment across surgery/
oncology. Multiple tests/ delays determining
eligibility.
T5 Vascular
surgery/
interventional
radiology
Main 18
(UK)
500–600 (UK)
3600
internationally
Surgery Surgery; stenting (2) Alternative care pathway for trial.
T6 Bariatric
surgery
Internal pilot
phase of a
main RCT
2 89 Surgery Banding; bypass
surgery (2)
Multiple tests/delays determining eligibility.
T7 Cancer Feasibility 2 Not set Surgery,
oncology
Surgery; radiotherapy
(2)
Recruitment across surgery/ oncology. Alternative
care pathway for trial.
T8 Cancer Feasibility 5 50 Surgery Radical surgery; partial
surgery (2)
Multiple tests/ delays determining eligibility.
GP general practitioner; RCT randomised controlled trial
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individual form was useful at multidisciplinary team
(MDT) meetings for trials with complex inclusion/exclu-
sion criteria, and when more extensive eligibility checks
needed to be completed before randomisation. T4 used
three forms, two centre screening logs (filled out pre
and post pre-trial treatment) and an individual form to
record further details about eligibility after pre-trial
treatment. T1 also performed more detailed centralised
eligibility checks on a CRF, filled out after participants
had consented to be randomised, in addition to basic eli-
gibility information recorded on the centre log.
Mapping the recruitment pathway
Initially, the thematic analysis of the eight trials’ screen-
ing logs identified six codes to classify all data collected:
screening instructions/number; patient identifiers/
demographic information; outcome of eligibility checks;
approaching patients; final decision about trial participa-
tion; and substudy-related information. Of the six codes,
four related to major stages of the recruitment pathway
and process:
 Screening: the identification of potentially eligible
participants and entry onto a screening or
recruitment log
 Eligibility assessment: checks against essential
inclusion/exclusion criteria in the trial protocol to
establish suitability for the trial
 Approach: the provision of information about the
trial and invitation to take part
 Randomised: randomisation outcome, or treatment
chosen by those declining randomisation
Data requested during these four stages of the recruit-
ment process are summarised in Table 2 and analysed in
further detail below.
Screening
This part of the process varied considerably between trials.
When potential participants were first identified and en-
tered onto the screening log (Screening), the majority of
trials recorded a date early in the recruitment pathway,
patient data (initials, gender, age, hospital ID, kept locally),
and a screening number. Three trials (T2, T5, T8) did not
assign screening numbers as they had a relatively straight-
forward pathway from initial identification to the results
of eligibility checks.
Half the trials (T1, T4, T6, T7) had straightforward
screening criteria, for example that all participants
referred for treatment X were potentially eligible. In gen-
eral, these trials were able to screen and conduct basic
eligibility checks on all potential participants referred for
treatment. T7 included three ‘initial trial eligibility’ cri-
teria in the protocol – ‘histology evidence of condition
X; no evidence of condition Y; fit for treatment’ to guide
MDT decision-making. Several trials (T2, T3, T8) de-
scribed a ‘potentially eligible participant’, (e.g. a person
diagnosed with condition X, fit for treatment Y), which
preceded the list of inclusion and exclusion criteria in
the trial protocol. Three trial protocols left more scope
for clinical judgement to identify individuals to screen
(T2, T3, T5). For example,
“Patients likely to require surgery X for condition Y
will be identified in outpatient clinics.” (T2)
“The screening log is to be filled out for all patients
considered for trial participation but subsequently
excluded.” (T3)
However, on the actual screening log, the instructions
were to only enter individuals with whom the trial
was discussed (T3):
“Please fill out details below for ALL patients with
whom T3 is discussed. Include patients who turn out
to be ineligible, and those who decline to consent.”
(Original emphasis)
One trial had no screening instructions or criteria,
only a description of eligibility, based on clinical
judgement alone (T5):
“Eligibility: Patient has X that is thought to need some
procedural intervention. Test shows intervention A and
intervention B are both anatomically practicable, but
both doctor and patient are substantially uncertain
whether intervention A or intervention B is preferable.”
Eligibility
All trials (except T5) included a comprehensive list of
inclusion and exclusion criteria in the trial protocol to
determine participant eligibility or exclusion. The major-
ity of inclusion and exclusion criteria were based on
clinical findings which would affect the suitability of an
individual to benefit from the treatments under investi-
gation. In T4, the term ‘ineligible’ was used to code a
range of clinical and non-clinical factors for non-
participation (e.g. different histology; logistical reasons
(unable to provide treatment within a specified time
frame); unable to be approached (too ill), patient prefer-
ences (patient refused).
All screening logs recorded the final outcome of eligibility
checks, using four different methods: Yes/No (T5), Yes/No
plus open text box to explain reason for ineligibility (T3,
T4, T8), a checklist against each inclusion/exclusion criter-
ion and final outcome (T4, T6, T7), or ineligibility, as a final
outcome of the screening process (T1, discussed in Rando-
mised section). In T6, surgeons were able to exclude pa-
tients for reasons other than the list of trial protocol
inclusion and exclusion criteria, with the reason why re-
corded as an open response. Two trials (T2, T4) used coded
responses to record the reasons for non-trial participation.
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For example, in T2, the inclusion and exclusion criteria
were printed on the back of the screening log, so the re-
search nurse could list multiple reasons why a potential
participant was excluded. Two trials (T1, T3) recorded clin-
ical data that could be useful to monitor how key eligibility
criteria were applied in different clinical centres.
Approached
Two trials did not record any information about ap-
proaching patients (T2, T3), which may reflect the
assumption that all participants entered into the
screening process and log were invited to take part in
the trial. Three trials (T1, T5, T6) recorded when
written information was provided. Four trials recorded
discussions with patients about the trial – either the
date of the recruitment appointment (T5, T6) and/or
whether the potential participant was approached for
consent (Yes/No), (T6, T7, T8). Reasons for not-
approaching patients were recorded in five trials,
using open responses (T1, T6, T7, T8), and as a
Table 2 Comparison of data recorded in the eight RCTs. Summary of data recorded using the SEAR framework
Screened NB any patient
identifiable data recorded on
screening log is not shared
with CTU
Eligible Approached Randomised?
T1 Patient initials, NHS number, age, gender,
screening ID, date of qualifying
intervention.
Screening criteria: Yes. Complete for all
patients referred for Treatment X
Ineligible recorded as final
screening outcome Reason for
ineligibility (open response)
Histology, pathology
Date two written information
sheets provided Non-approach
recorded as final screening
outcome Reason for non-approach
(open response)
Randomisation ID and allocation
If not randomised, reason for
non-participation
(open response)
T2 Patient initials, gender, date of
potential recruitment. Screening
criteria: No
Reason for exclusion or ineligibility
(using coded inclusion and
exclusion criteria printed on back
of the log)
Not recorded Reason for eligible patients
declining the trial (6 codes) Final
treatment recorded for all
screened participants Treatment
preferences for eligible decliners
T3 Patient initials, age, screening ID,
date screening initiated. Screening
criteria: Yes. Complete for all
patients with whom the trial is
discussed.
Clinical data – nodal status (+/),
tumour size Was the patient
eligible? (Y/N) Reason for
ineligibility (open response)
Not recorded Consent (Y/N) for main and two
substudies and participant ID
Reason to decline main study
and two substudies
(open response) Final treatment
received for all screened
participants
T4 Patient initials, screening ID, age
range, gender, MDT date. Screening
criteria: Yes. Complete for all
patients referred for Treatment X
MDT decision – potentially eligible
(Y/N) and reason (open response);
eligibility checked against each
inclusion/exclusion criteria; Final
MDT decision eligible (Y/N). If not,
reason recorded (coded and/or
open response).
‘Reason not eligible’ includes 3
coded responses why patient
not approached
Randomisation ID Reason
eligible patients decline trial
(open response) Treatment
received by non-randomised
patients
T5 Patient initial, gender, age,
hospital ID, referral from
(5 codes). Screening
criteria: No.
Eligible (Y/N) Written information given (Y/N)
Date trial discussed
Randomisation ID Patient
consent (Y/N). If no, record
reason Final treatment decision
(non-randomised patients)
T6 Patient name, study ID, hospital
number. Screening criteria: Complete
for all patients referred for intervention
X. Kept on site form – not entered into
database if patient does not join the trial.
Eligibility (Y/N) against all trial
inclusion/ exclusion criteria
Written information given (Y/N),
date provided, reason not given
(open response) Date of trial
discussed Approached to
participate in trial (Y/N) and reason
not approached (open response)
Coded when added to the study
database
Reason eligible patient declined
consent Final treatment decision
(non-randomised patients)
Coded when added to the
study database
T7 Patient initials, date of birth, study
number, gender, date of MDT decision,
pathology. Screening criteria: Yes. 3
‘initial’ trial eligibility criteria
Eligibility against all trial inclusion/
exclusion criteria (Y/N). Reason for
ineligibility (open response)
Patient invite to join study (Y/N).
Reason (2 codes/open response)
Reason eligible patient declined
trial (open response) Final
treatment received (non-
randomised patients)
T8 Patient initials, NHS no., date
first screened. Screening criteria:
Please enter all patients
recommended by MDT as
potentially eligible for Trial X
Inclusion/exclusion criteria met
(Y/N) Reason for ineligibility
Provision of written information
(Y/N) Approach consent for trial
(Y/N)
Consent given (Y/N) Randomised
(Y/N) Reason eligible patients
declined (open response)
CTU Clinical Trials Unit, MDT multidisciplinary team, NHS National Health Service, RCT randomised controlled trial, SEAR Screened, Eligible,
Approached, Randomised
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subset of codes under ‘reasons for ineligibility’ (T4).
Only T6 recorded both written and oral information
provision, and reason for not approaching an eligible
or potentially eligible participant.
Randomised - Final screening outcome and treatment
allocation or selection
All screening logs captured information about the final
screening outcome and reasons for non-participation. The
final outcome of the screening process was most clearly
recorded in T1, using four codes - randomised (1),
declined (2), ineligible (3), not approached (4). In the next
column, an open text box recorded reasons for non-
participation, or if enrolled, randomisation ID and treat-
ment allocation. This open text box optimised the use of
space to record any reason for non-eligibility (e.g. the clin-
ical result which made the person ineligible); reason for
non-approach (e.g. patient not approached in error,
patient too unwell to approach); and the reason to decline
the trial (e.g. patient did not want treatment X). In this ex-
ample, it was clear the final column should be filled out
for all participants screened.
The quality of data recorded in open text boxes was
sometimes limited due to insufficient space, use of open
text boxes for multiple answers, and/or it was unclear
for which patients the box should be completed. Several
trials recorded the reasons why eligible participants de-
clined using three or six coded responses (T2, T5). In
addition, T2 recorded the treatment preferences for de-
cliners and final treatment outcome for all screened par-
ticipants. Five trials (T2, T4, T5, T6, T7) requested
information about the final treatment received by non-
randomised patients, although this was not always re-
corded on the screening log.
The ‘optimised’ SEAR log
Results from the content analysis were synthesised to
develop an optimised screening and recruitment log to
record key aspects of the recruitment pathway. An
exemplar ‘clinical centre’ log is shown to demonstrate
how data can be captured in a simple format and
adapted for use in most trials (Fig. 1), with recommen-
dations for data collection summarised in Table 3. The
SEAR framework could also be adapted to collect data
using other formats, for example, a CRF-style form or
automated database (as in T4, T6, T7).
Discussion
CONSORT guidelines emphasise the importance of
recording some basic aspects of screening and eligibility
assessment before randomisation, but there has been lit-
tle consensus over how much data to collect or how best
to do this. We compared the content of screening/re-
cruitment logs in eight comparatively small hospital-
based RCTs with an integrated QRI which encouraged
the keeping of such logs. This content was synthesised
Fig. 1 SEAR ‘clinical centre’ log
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to develop a simple framework that could be used or
adapted to suit most RCTs, particularly those with re-
cruitment difficulties and multiple clinical centres. The
SEAR (Screened, Eligible, Approached, Randomised)
framework supports the collection of information that
can be used to identify recruitment obstacles which can
then be addressed in order to improve the recruitment
process.
With so many trials failing to enrol sufficient numbers,
recruitment challenges have been well documented –
lower than expected numbers of referrals or eligible pa-
tients, organisational issues at recruiting centres, problems
with the trial design, complex clinical or recruitment
pathways, and lack of clinician and patient equipoise
[5, 15–18]. Some of these problems could be identi-
fied through the collection and analysis of screening
data, but few trials collect or publish information
about participants before randomisation, beyond the
numbers necessary to meet CONSORT guidelines [3,
10]. The SEAR framework augments CONSORT
guidelines, and, building on the findings of QRIs, rec-
ommends the recording of the number of potential
participants excluded because they were not
approached, and the reasons why potential partici-
pants were excluded from the trial (i.e. reason for
ineligibility, non-approach, declined), as well as the
final treatment received by eligible patients.
Logging the progress of potential participants through
eligibility checks to final decision about trial participa-
tion and treatment is relevant to all clinical trials. How-
ever methodological interest in screening data has been
somewhat limited to emergency medicine trials in rela-
tion to concerns about selection bias and the generalis-
ability of trial results [19, 20], in population-based
cancer screening studies to increase clinical trial partici-
pation [21, 22] and less frequently as a tool to monitor
trial eligibility and recruitment rates [23].
The SEAR framework defines four key stages in the re-
cruitment process where participants may be lost, and
provides recommendations for data collection. The
SEAR framework requires trial-specific adaptations and
instructions to harmonise recruitment practices in mul-
ticentre trials and optimise the use of resources to iden-
tify trial-specific recruitment problems. Unnecessary
screening can be minimised through trial-specific cri-
teria for entry into the SEAR process. In practice, the
distinction between Screening (initial identification and
entry into the SEAR log) and Eligibility assessments
(against essential trial inclusion and exclusion criteria),
may be blurred in some trials. Time and effort may be
wasted screening large numbers of participants who turn
out to be ineligible. Other RCTs or clinical centres may
take a minimalistic approach to screening, so that only
participants deemed highly likely to be eligible are
approached to join the trial and entered onto the screen-
ing or recruitment log. In trials with small numbers of
eligible patients, it may be beneficial to conduct eligibil-
ity checks on a larger number of patients to understand
key reasons for ineligibility. Although the final outcome
of eligibility checks may not be confirmed before pa-
tients are approached for trial participation, the SEAR
log has been designed to capture information over time
(eligibility pending, or awaiting patient decision) and
flexibly, according to trial-specific recruitment priorities
and concerns.
Least attention has been devoted to define when and
how to approach potential participants, although this is
where many are often lost [5, 15]. To optimise the num-
ber of potential participants approached to join an RCT,
we recommend logging the date written information is
provided, when the trial is discussed, and when a partici-
pant is invited to join the trial. Regarding eligibility, we
also recommend data about key eligibility criteria are
recorded so that it is possible to identify local decision-
making, and final treatment selected or received by non-
randomised eligible patients.
Doubts about the scientific value of screening data have
led some to argue that the effort to collect high-quality
screening data outweighs any benefit [24]. In particular,
concerns have been raised about the lack of standardised
Table 3 Recommended SEAR log checklist
Screened Eligible
• Develop criteria for entry into the screening process and include
instructions on the SEAR log (ideal)
• Record basic patient details:
age, gender, screening ID, initials (kept locally)
• Record basic clinical
data for key screening or eligibility criteria as appropriate
• List the inclusion and exclusion criteria on front or back of SEAR log
• Note final outcome of eligibility checks against trial inclusion and
exclusion criteria
• Record reason ineligible using trial inclusion
and exclusion codes
Approached Randomised?
• Date written information provided
• Date trial discussed and recruiter
initials
• Invited to take part in trial (Y/N)
• Record reason for non-approach
• Final outcome of screening process
(ineligible, not-approached, declined, randomised)
• Record reason to decline the trial
• Treatment received by eligible patients outside the trial
(recorded on screening log or elsewhere as appropriate)
SEAR Screened, Eligible, Approached, Randomised
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criteria for screened participants and differences in site
processes that make the collection of uniform data prob-
lematic in multicentre trials. The collection of screening
data can be difficult and time-consuming, and may not be
needed in detail for all trials, but qualitative research in
QRIs has indicated its value. Suboptimal screening can
limit the number of potentially eligible patients given the
opportunity to enrol in an RCT [25]. Recruiters often
struggle to reconcile the desire to gather robust evidence
with their clinical instincts and concerns about patient eli-
gibility and safety [5].
Screening data collected by the CTU has been ana-
lysed by QRI researchers to help identify these clear ob-
stacles and more subtle hidden challenges so that they
can be addressed [15] – for example identifying lower
than anticipated numbers of eligible patients and differ-
ences between clinical centres in eligibility assessment
[10, 26, 27]. Previous research has shown trialists some-
times experience discomfort offering the RCT to all
patients, even though the patient technically meets all
the trial inclusion and exclusion criteria [5, 15]. Identify-
ing differences in the interpretation of eligibility criteria
can be useful to target training and support to improve
clinician equipoise [5, 15, 28]. Screening data were also
discussed in feedback sessions to address hidden chal-
lenges [15, 25], and analysis of final treatment received
informed feedback and training sessions to improve
equipoise in another trial [26].
There are further examples of the usefulness of log
data in the eight RCTs included here. In T1, screening
data helped to ensure potential trial participants were
identified, logged and provided with information about
the trial early in the pathway. Screening practices were
particularly important because the condition was rare,
and coordination was required across two specialties.
Data were also used to identify high volume centres, so
that additional training and support could be targeted to
improve the recruitment rate in centres screening the
most potentially eligible participants. Given greater
interest in embedded recruitment studies [29, 30],
screening data can provide important information to
evaluate the effectiveness of recruitment interventions.
The Screened, Eligible, Approached, Randomised
(SEAR) framework supports the collection of data as a
tool to map the recruitment process and identify barriers
to recruitment. It can be particularly helpful in pilot or
feasibility studies, to assess feasibility and inform recruit-
ment strategies for a main trial. Data for the SEAR log
can be collected according to the preferred method of
the CTU and/ or clinical centres, in the centre log for-
mat, using a CRF-style form, or an as app or iPad with
supporting database. The SEAR framework and log have
been designed so they can be adapted to monitor re-
cruitment in any RCT, but is likely to add most value in
trials where recruitment problems are anticipated or evi-
dent, and in multicentre trials.
There are some limitations to this study and the
framework. The trials included in this study had inte-
grated QRIs, and so there was already a heightened
awareness of recruitment issues. The sample size, al-
though small, did include main trials, feasibility, and
pilot studies. However, we did not find notable differ-
ence between different types of studies. Three out of five
pilot/feasibility studies have progressed to a main trial,
and are currently using a similar screening log to map
the recruitment pathway in the main trial with an inte-
grated QRI. Other trials may find it more difficult to col-
lect such data and it is recommended that the resources
needed to support the collection and management of
SEAR data are adequately costed for in the grant
proposal.
The RCTs sampled here were all National Health
Service (NHS) hospital-based studies, evaluating treat-
ments for non-emergency procedures for cancer or
chronic conditions. The total number of patients
screened for each trial was comparatively small. Much
larger trials or trials identifying patients from primary
care may need to conduct basic eligibility checks before
entering patients into the SEAR process, to streamline
the SEAR framework, or may not need it in full. The
SEAR process can be time-consuming and requires re-
sources from recruiting centres which may be a problem
for some RCTs and CTUs. However, the investment may
reveal information about recruitment difficulties that re-
main such a source of difficulty for many RCTs. The
framework could be a useful tool in emergency medi-
cine trials, where it is important to closely monitor
the appropriateness and application of eligibility cri-
teria [19, 20].
The SEAR framework and logs included in this study
collected information exceeding the CONSORT report-
ing guidelines, and National Institutes of Health (NIH)
(2014) definition of a screening log [11]. However, the
CONSORT guidelines conflate screening criteria with
eligibility criteria, and eligibility criteria with those
approached for study participation. Previous syntheses
of qualitative research [4, 5] and findings from the con-
tent analysis here show that the recruitment pathway in
most trials follows the SEAR stages: Screening, Eligibil-
ity, Approached, Randomised. As such, the SEAR frame-
work could be used to update CONSORT reporting
guidelines, following further work to test and validate
this approach in other types of trials, with different
groups of investigators and outside the NHS context.
Although CONSORT was extended to improve pilot and
feasibility study reporting, the guidelines did not sub-
stantially revise data on screening except for reporting
numbers approached [31].
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Conclusions
The SEAR framework provides a systematic way to rec-
ord the flow of potential participants through the
recruitment process. It can be adapted to monitor and
identify problems in the recruitment pathway of most
trials. The reasons and points at which people are ‘lost’
to the trial can be further investigated using qualitative
methods or targeted interventions within a QRI to im-
prove recruitment [6]. Data collected using SEAR can
also be used to evaluate the QRI or other interventions
aimed to improve recruitment. Given that most trials
collect some data about potential participants during the
recruitment process to meet current CONSORT guide-
lines, the SEAR framework is a low-intensity interven-
tion to support better recruitment practices in clinical
trials, and further work to test it more widely is
recommended.
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